Research programme: albumin and antibody drug conjugates - CytRx

Drug Profile

Research programme: albumin and antibody drug conjugates - CytRx

Alternative Names: AE-Ester-Sulf07; AE-Keto-Sulf07; DK 049; FN296; LADR-10; LADR-7; LADR-8; LADR-9; PP072

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytRx Corporation
  • Class Antineoplastics; Auristatins; Biological toxins; Drug conjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Research Liver cancer

Most Recent Events

  • 18 Apr 2018 Adverse events and pharmacodynamics data from a preclinical trials in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2018 )
  • 15 Mar 2018 Adverse events and pharmacodynamics data from a preclinical trial in Cancer released by CytRx Corporation
  • 15 Mar 2018 CytRx Corporation plans clinical trials for LADR 7 (AE-Keto-Sulf07), LADR 8 (AE-Ester-Sulf07), LADR 9 (PP072) and LADR 10 (FN296) for Cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top